Malignant Pleural Mesothelioma (MPM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Malignant Pleural Mesothelioma (MPM) Market Outlook

Thelansis’s “Malignant Pleural Mesothelioma (MPM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Malignant Pleural Mesothelioma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Malignant Pleural Mesothelioma (MPM) Overview

Malignant pleural mesothelioma (MPM) is a highly aggressive cancer affecting the pleural surface, often stemming from prior asbestos exposure, typically manifesting around 40 years after initial fiber exposure. The majority of MPM patients initially present with breathlessness, chest pain, or both. Early-stage breathlessness typically stems from pleural effusion, evident in 70% of patients at presentation. However, as the disease progresses, pleural effusions tend to decrease, either due to medical intervention or obliteration of the pleural space by the tumor. Additional symptoms may include fatigue, anorexia, weight loss, sweats, and malaise. Histologically, MPM presents in four main sub-types: epithelioid, sarcomatoid, biphasic or mixed, and desmoplastic. The sarcomatoid variant is notably associated with the poorest outcomes, boasting a median survival of only 4 months. In contrast, the epithelioid sub-type offers the most promising prognosis, with a median survival of 13.1 months. The prognosis for MPM is grim, with median survival falling between 8 to 14 months post-diagnosis. Although women generally exhibit a more favorable prognosis, the disease primarily affects men due to its occupational origins, with a male predominance of 4:1. The risk of developing MPM correlates with the type of fiber encountered, as well as the intensity and duration of exposure. Currently, no curative treatment exists for MPM. Systemic treatment modalities encompass chemotherapy, targeted therapy, and radiotherapy, administered individually or as part of multimodal therapy approaches.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: